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A core microbiome associated with the peritoneal
tumors of pseudomyxoma peritonei
Jeremy J Gilbreath1, Cristina Semino-Mora2, Christopher J Friedline3, Hui Liu2, Kip L Bodi4, Thomas J McAvoy5,
Jennifer Francis6, Carol Nieroda6, Armando Sardi6, Andre Dubois2, David W Lazinski7, Andrew Camilli7,8,
Traci L Testerman9 and D Scott Merrell1*

Abstract
Background: Pseudomyxoma peritonei (PMP) is a malignancy characterized by dissemination of mucus-secreting
cells throughout the peritoneum. This disease is associated with significant morbidity and mortality and despite
effective treatment options for early-stage disease, patients with PMP often relapse. Thus, there is a need for
additional treatment options to reduce relapse rate and increase long-term survival. A previous study identified the
presence of both typed and non-culturable bacteria associated with PMP tissue and determined that increased
bacterial density was associated with more severe disease. These findings highlighted the possible role for bacteria
in PMP disease.
Methods: To more clearly define the bacterial communities associated with PMP disease, we employed a
sequenced-based analysis to profile the bacterial populations found in PMP tumor and mucin tissue in 11 patients.
Sequencing data were confirmed by in situ hybridization at multiple taxonomic depths and by culturing. A pilot
clinical study was initiated to determine whether the addition of antibiotic therapy affected PMP patient outcome.
Main results: We determined that the types of bacteria present are highly conserved in all PMP patients; the
dominant phyla are the Proteobacteria, Actinobacteria, Firmicutes and Bacteroidetes. A core set of taxon-specific
sequences were found in all 11 patients; many of these sequences were classified into taxonomic groups that also
contain known human pathogens. In situ hybridization directly confirmed the presence of bacteria in PMP at
multiple taxonomic depths and supported our sequence-based analysis. Furthermore, culturing of PMP tissue
samples allowed us to isolate 11 different bacterial strains from eight independent patients, and in vitro analysis of
subset of these isolates suggests that at least some of these strains may interact with the PMP-associated mucin
MUC2. Finally, we provide evidence suggesting that targeting these bacteria with antibiotic treatment may increase
the survival of PMP patients.
Conclusions: Using 16S amplicon-based sequencing, direct in situ hybridization analysis and culturing methods, we
have identified numerous bacterial taxa that are consistently present in all PMP patients tested. Combined with
data from a pilot clinical study, these data support the hypothesis that adding antimicrobials to the standard PMP
treatment could improve PMP patient survival.
Keywords: PMP, Pseudomyxoma peritonei, Peritoneal cancer, Microbiome, Microbiota
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Background
Pseudomyxoma peritonei (PMP) is a clinical syndrome
characterized by the dissemination of mucus-secreting
tumors throughout the peritoneal cavity [1-3]. This rare
but devastating condition usually arises after rupture of
a mucin-producing appendiceal neoplasm and is associated with significant morbidity. Mortality usually results
from diffuse spread of mucin within the peritoneum and
mechanical obstruction of the intestines. PMP is generally classified into two major categories: diffuse peritoneal adenomucinosis (DPAM) and peritoneal mucinous
adenocarcinoma (PMCA) [3-5]. DPAM is the lower
grade of PMP disease and refers to an indolent tumor
form without cellular atypia and with no invasive
features. In contrast, PMCA is characterized by severe
cellular atypia, poor histologic cellular differentiation
and tissue invasion. When proper treatment is given in a
timely manner, the prognosis for patients with DPAM
can be good (five year survival rate of ~75%); however,
patients with the more severe PMCA do not fare as well
(five year survival rate of ~14%) [6]. Current therapeutic
strategies consist of macroscopic tumor and mucin removal by cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy [3,5,7,8]. However,
despite aggressive treatment, the disease frequently
relapses and the ten year survival is only 32% [1,9,10].
As such, there is a great need for ways to improve longterm patient outcome.
Within the past several years, it has become increasingly clear that the microbial communities in and on the
human body have a far-reaching impact on human
physiology and serve to maintain the balance between
health and disease states [11-21]. More recently these interactions have been linked to human cancers [12,17]
and have even led researchers to identify particular bacterial taxa that are enriched in tumor environments
compared to surrounding tissue [12,17]. These insights
not only provide novel information about tumor development and subsequent disease progression, but also
highlight potential treatment options for these cancers.
Using probes designed to recognize both typed and
non-culturable bacteria (TNCB), as well as the known
bacterial carcinogen Helicobacter pylori, a recent study
observed that there are numerous types of bacteria,
which are associated with the PMP tumors and secreted
mucin within the normally sterile peritoneal cavity [10].
In PMP tissue, the density of TNCB and H. pylori was
highest in the more malignant form of PMP; however,
the identity of these TNCB was not determined. Taken
together, those results suggested that PMP disease progression may be associated with the presence of bacteria
within the peritoneum.
We hypothesize that bacteria play a role in the progression or maintenance of PMP disease. In the current
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study, we utilized high-throughput sequencing of amplicons from the V6 hyper-variable region of the 16S
ribosomal RNA (rRNA) gene to characterize the bacterial communities associated with tumors and secreted
mucin in 11 PMP patients. We identified a highly conserved core group of bacterial taxa that were found in
all patients. The core community membership was consistent across all patients tested, although the relative
abundance of these bacteria varied from patient to patient. Specific DNA probes and in situ hybridization
(ISH) was used to directly detect PMP community members across a range of taxonomic depths. Furthermore,
multiple bacterial isolates were obtained by culturing
PMP tissue samples under microaerophilic conditions;
some of these isolates interact with the PMP-associated
mucin MUC2 as well as host cells in vitro. Based on
these and previous findings [10], we initiated a pilot clinical study to evaluate the possibility of using antibiotic
therapy to target these bacterial communities in the
treatment of PMP. Consistent with the hypothesis that
these bacteria play a role in PMP disease, our preliminary clinical findings suggest that treating PMP patients
with antibiotics early in disease progression may increase
long-term survival.

Methods
PMP patients

This study utilized stored PMP patient specimens that
were collected peri-operatively at Mercy Medical Center
in Baltimore, MD. Tissue was aseptically collected in a
sterile surgical suite and stored at −80°C until the samples were ready to process. Free mucin was collected
from the peritoneal cavity, and tumor tissue was biopsied from the peritoneal wall; by following these guidelines, the two sample types are visually distinguishable
from one another. All procedures were approved by the
IRB at all centers involved in this study. Written informed consent was obtained from all patients prior to
enrollment in the study.
The study was in compliance with the Helsinki Declaration and was approved by the Institutional Review
Boards of the Mercy Medical Center and the Uniformed
Services University of the Health Sciences. Written informed consent was obtained from all patients before
study entry.
DNA extraction, V6 PCR and sequencing

Total genomic DNA was isolated from PMP tissue specimens and stored at -80C. Between 100-200 ng of genomic
DNA was used as template for PCR with a combination of
V6-specific primers as previously described [22,23]. The
products of 2–3 amplifications from each sample were gel
purified and pooled. For each set of amplifications, a no
template control was included to ensure that amplification
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was not the result of DNA contamination. Additionally,
reagents used for DNA elution were tested for contaminating bacterial DNA by PCR. Pooled amplicons
were barcoded, combined into a multiplexed sample
and sequenced on an Illumina HiSeq2000 at the Tufts
University Core Facility. Raw reads were de-multiplexed,
filtered for quality and barcodes/adapters were removed
using Galaxy [24].
V6 sequence processing and analysis

All subsequent sequence analyses were performed using
mothur [25]. To simplify the dataset, each sample was
randomly sub-sampled to a depth of 100,000 reads per
sample. Sequences were aligned to a V6-specific, curated
database [22] derived from the full-length SILVA
alignment distributed with mothur. The alignment was
screened to remove sequences that were shorter than
56 bp or greater than 72 bp in length as well as any
sequences that contained an ambiguous base call or homopolymer runs of >4 bp. The resulting alignment was
then filtered to remove any columns that contained
missing information. Reads were pre-clustered so that
any sequences that contained a single base pair difference were considered to be the same. Pre-clustered
reads were classified using the mothur implementation
of the RDP Bayesian classifier [26] using a cutoff of 60%
bootstrap support over 100 iterations. Sequences that
were classified as mitochondria, cyanobacteria, chloroplasts and sequences that were classified as “unknown,”
or “unclassified” at the phylum level were removed from
the dataset. The remaining aligned sequences were used
to generate a pairwise distance matrix and clustered
into operational taxonomic units (OTUs) using averagelinkage clustering at an identity of 97%. OTUs were
classified using the mothur implementation of the RDP
classifier as described above. Prior to α- and β-diversity
calculations the sequences from each sample were normalized based on the lowest number of OTUs found in
any of the samples. As indicated by Good’s coverage
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estimate, this workflow provided ample sample coverage
(range of coverage was 0.96 to 0.99, with a mean coverage of 0.976).
In situ hybridization (ISH) studies

16S and 23S rRNA-specific probes used for ISH are
listed in Table 1. The Actinobacteria, Bacteroidetes,
Betaproteobacteria, Gammaproteobacteria, Firmicutes,
Rhizobiales, Pseudomonas, Streptococcus and Verrucomicrobiales probe sequences were obtained from
probeBase (retrieved from: http://www.microbial-ecology.
net/probebase). The Propionibacterium-specific probe was
designed using 47 randomly selected full-length Propionibacterium 16S sequences obtained from the RDP database. The specificity of the probe sequence was verified
using the ProbeMatch function on the RDP website; the
probe sequence used detects ~97% of sequences classified
into the Propionibacterium genus. Labeling and hybridization procedures were performed as previously described [10]. Briefly, formalin-fixed tissue blocks were
cut into 5 micron sections; each unstained section was
deparaffinized, pre-hybridized and subsequently treated
with denatured probe solution for 18 h at 37°C. The
hybridization mixture contained one of the 10 different
biotinylated taxa-specific probes. After hybridization,
unbound probe was removed by successive washes in
decreasing concentrations of SSC (2× SSC for 30 min, 1×
SSC for 10 min, 0.5× SSC for 10 min and 0.1× SSC for
15 min at 60°C). Probes were detected using a streptavidin
conjugated with fluorescein (FITC). To ensure that the
FITC-conjugated secondary did not interact with the tissue non-specifically and to control for background fluorescence, we performed control hybridizations without the
addition of the primary probe. Sections were mounted
with Vectashield (Vector Labs, Burlingame, CA), and reactions were observed using a Nikon Eclipse 80i microscope
with a DS camera, a DS-L2 control unit and an NISElements scope. Control hybridizations for nonspecific
binding were performed for all probes used in this study.

Table 1 ISH probes used in this study
Probe (Abbreviation)

Taxonomic depth

Sequence (5’-3’)

Target

Actinobacteria (ACT)

Phylum

TATAGTTACCACCGCCGT

23S rRNA

Bacteroidetes (BAC)

Phylum

AGCTGCCTTCGCAATCGG

16S rRNA

Firmicutes (FIR)

Phylum

TGGAAGATTCCCTACTGC

16S rRNA

Class

CCCATTGTCCAAAATTCCCC

16S rRNA

Betaproteobacteria (BET)
Gammaproteobacteria (GAM)

Class

GCCTTCCCACATCGTTT

16S rRNA

Rhizobiales (RHI)

Order

TCGCTGCCCACTGTCACC

16S rRNA

Verrucomicrobiales (VER)

Order

GCTGCCACCCGTAGGTGT

16S rRNA

Pseudomonas (PSE)

Genus

TCTGGAAAGTTCTCAGCA

16S rRNA

Propionibacterium (PRO)

Genus

CACCCATCTCTGAGCACCCCG

16S rRNA

Streptococcus (STR)

Genus

CCACTCTCCCCTTCTGCAC

16S rRNA
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Culturing and identification of bacterial isolates from PMP
tissue

Aseptically collected surgical specimens were shipped
overnight on ice to the LSU Health Sciences Center
Shreveport. As H. pylori was previously identified in PMP
tissue [10], initial culture conditions were chosen to be
suitable for cultivating this organism. Upon receipt,
amounts of material weighing up to 1 gram were placed
in microcentrifuge tubes containing 2 mm zirconium
oxide beads and homogenized for four minutes using a
Bullet Blender (Next Advance, Inc., Averill Park, NY).
Twenty-five to two hundred microliters of each homogenate was added to 25 cm2 tissue culture flasks containing
5 ml Ham’s F-12 Nutrient Mixture supplemented with 2%
fetal bovine serum (fbs), 12.5 μg/ml nicotinamide adenine
dinucleotide (NAD), and 3 μg/ml cytochalasin B. Cytochalasin B was used to inhibit phagocytosis of bacteria by
macrophages. Flasks were incubated in microaerobic conditions, monitored daily for growth and sub-cultured once
growth was observed. Each isolate was serially passaged
multiple times until the culture was axenic. Full-length
16S rRNA gene sequences were PCR amplified using
FideliTaq high fidelity polymerase (USB) and the 8F and
1492R primers; amplicons were sub-cloned into pGEM-T
Easy (Promega). Cloned 16S rRNA genes were sequenced
with 1492R and 907R primers. Sequences were classified
using the web-based RDP Bayesian classifier (http://rdp.
cme.msu.edu) and the RDP training set 9. Adherence assays were performed by co-culturing selected isolates with
HT-29 cells, which produce the PMP-associated mucin
MUC2. Interaction with MUC2 was detected by immunohistochemistry. Briefly, in vitro MUC2 production was
detected using a polyclonal anti-MUC2 antibody; the
MUC2::MUC2 antibody conjugates were detected using
biotinylated anti-rabbit antibody and avidin-peroxidase.
To ensure that the signal detected was specific to MUC2,
we also performed control hybridizations with non-MUC2
secreting cells, as well as MUC2 secreting cells in the absence of bacteria.
Clinical trial study design

A pilot clinical study was initiated to evaluate the possible
association between bacteria and the development of PMP
disease and to determine the benefit of antibiotic treatment.
Beginning in September of 2007, a group of 21 patients with
PMP was treated with antibiotics in conjunction with the
standard cyroreduction surgery and hyperthermic intraperitoneal chemotherapy treatment with mitomycin C. The
treatment group was comprised of eight patients with
DPAM, 11 with PMCA, one patient with both diagnoses
and one patient with no available diagnosis. Patients were
treated with Prevpac®, which includes 30 mg lansoprazole,
500 mg amoxicillin, and 500 mg clarithromycin; For each
course of treatment, antibiotics were taken twice daily for
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10–14 days. Lymph node status was determined by a pathologist at Mercy Medical Center, Baltimore, MD; positive
lymph nodes were identified by the presence of cancer
cells. Patient survival was compared using a log-rank statistical test.

Results
Sequence analysis and identification of a core PMP
Microbiome

A previous ISH-based study identified the presence of
many typed and non-culturable bacteria in tissue samples taken from PMP tumors and secreted mucin [10].
This study highlighted the possibility that these bacteria
play a role in PMP disease progression; thus, these bacteria could be targeted with antibiotics as a novel, ancillary therapeutic option. In order to investigate the
presence of these bacteria further, we collected paired
tissue samples from 11 PMP patients (11 tumor and 11
mucin samples = 22 total) that had not been given antibiotic treatment, and used a V6-based analysis to profile
the bacterial communities associated with both tumor
and secreted mucin.
After clustering sequences into OTUs at a level of 97%,
we first examined the community profiles at the phylum
level. As shown in Figure 1, the distribution of bacterial
phyla between samples was consistent; the most prominent
phylum represented in all samples was the Proteobacteria.
The relative abundance of the Proteobacteria across the 22
samples ranged from 56.8% to 90.2%, with a mean of 73.0%.
Other prominent phyla include the Actinobacteria (3.4% to
19.3%, mean of 10.7%), Firmicutes (1.3% to 17.8%, mean
of 6.9%), Bacteriodetes (2.0% to 14.8%, mean of 7.2%),
Verrucomicrobia (0.3% to 1.7%, mean of 0.8%), Acidobacteria
(0% to 0.6%, mean of 0.3%), TM7 (0% to 0.3%, mean of 0.1%)
and OD1 (0% to 0.9%, mean of 0.2%).
The observed richness (number of OTUs) across the
individual samples ranged from 388 to 1833, with a mean
of 1045. Rarefaction curves for individual tumor and
mucin samples are depicted in Additional file 1: Figure S1,
and indicate that further sampling would likely not significantly affect observed richness. While the number of
OTUs varied between sampled body sites (tumor vs.
mucin) in some patients, as a whole, the number of OTUs
found in tumor tissue was not significantly different than
that found in the free mucin (P = 0.24, Student’s t-test). As
the microenvironment of tumor tissue may be quite different than free mucin, we tested for OTU enrichment based
on tissue type (tumor vs. mucin) using the mothur implementation of Metastats [27]. Surprisingly, the number of
sequences clustered into each OTU was not significantly
different in either site, further highlighting the fact that
the bacterial communities in the tumor and mucin tissue
sites are highly similar. Furthermore, when we compared
the differences between tumor and mucin community
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Figure 1 Distribution of prominent bacterial phyla. The relative abundance of each phylum is shown as the number of OTUs that were
classified in each phylum out of the total number of bacterial OTUs. Numbers on the X-axis represent patient designations. “T” indicates the
sample was taken from tumor tissue and “M” indicates the sample was taken from mucin.

membership and relative abundance using the classic
Jaccard and Yue & Clayton (thetaYC) indices, we found
that the two communities were not significantly different
(P = 0.947, AMOVA using Jaccard indices; P = 0.83,
AMOVA using thetaYC indices). Given the apparent similarity between the tumor and mucin communities, we
combined the sequence sets from the tumor and mucin
for each patient (a combined total of 200,000 randomly
sampled sequences from each patient). Using these combined datasets, we again compared the differences in community membership and relative abundance using the
classic Jaccard and thetaYC indices, respectively. As shown
in Figure 2, the membership of the communities in each
patient displays a surprisingly high level of similarity. Between patients, the only differences seem to be in terms of
relative abundance of community members (Figure 2B)
rather than the types of taxa present (Figure 2A). For example, the thetaYC-based comparison between patients
141 and 144 (Figure 2B) indicates that the communities in
these two patients differ in terms of the relative abundance of taxa present. This finding may be explained by
community differences at both higher and lower taxonomic levels. As shown in Figure 1, at the phylum level
there were more Proteobacteria present in the samples
obtained from patient 141 than 144, whereas the number
of Actinobacteria were greater in patient 144. At the genus
level, patient 141 had approximately two times as many
Helicobacter sp. compared to patient 144, and patient 144
had approximately 10 times as many Propionibacterium
sp. compared to patient 141 (data not shown). Thus, differences in large taxonomic groups as well as individual
taxons likely contribute to the community differences observed between PMP patients.

Given the overall similarity between the tumor and
mucin communities in a given patient we decided to use
the combined tumor and mucin V6 sequence sets for
each patient and asked whether there was a core set of
sequences that were present in all patients. For a particular sequence to be considered as part of this core
microbiome, we took a conservative approach and required that an exact match to a particular sequence be
present in all patients. As shown in Figure 3, there were
four phyla represented in the PMP core microbiome; the
relative abundance of each phyla was similar to what
was seen for the individual tumor and mucin samples,
with the majority of sequences being classified as
Proteobacteria (77%), followed by Actinobacteria (15%),
Firmicutes (5.7%) and Bacteroidetes (2.3%). Within these
phyla the core microbiome can be further broken down
into 34 different groups that were classifiable to the
genus level. A breakdown of this subset of sequences is
shown in Table 2 and Additional file 1: Figures S2-S5,
and a complete list of taxa identified in the PMP core
microbiome is shown in Additional file 1: Table S1.
While many of these taxa such as Escherichia, Propionibacterium, Streptococcus and Helicobacter are commonly
found in humans, some of the taxa represented are more
typically categorized as environmental organisms.
Direct detection of selected members of the PMP
microbiome

As a complementary approach to our sequencing analysis, we used DNA probes complementary to taxonspecific regions of the 16S and 23S rRNAs to detect a
subset of the taxa identified in the sequence-based analysis by in situ hybridization (ISH) (Table 1). For these
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Figure 3 Core set of sequences found in all PMP patients. After
combining the tumor and mucin sequence sets for each patient,
sequences that were present in all patients were classified at a
distance of 97%. The relative abundance of these sequences at the
phylum level is shown.

Figure 2 β-diversity between PMP communities. Heatmaps
compare the classic Jaccard (Jclass) dissimilarity indices (A) and
thetaYC indices (B) for bacterial communities found in PMP patients.
Numbering along the left-hand and top sides of each heatmap
represent individual patient designations. Each square within the
heatmap represents a single pairwise comparison between the
corresponding patient communities (labeled at the top and left side
of each heatmap). As indicated by the bar below each heatmap,
comparisons in which the communities are more dissimilar are more
red, whereas communities that are more similar are less red.

experiments we utilized tissue sections from three patients
that were included in the sequencing study (patients 135,
149 and 196) and two additional patients that were not
included in the sequence-based analysis (patients 145
and 244). Figure 4 shows a representative subset of
these results; hybridizations with the Firmicutes (FIR),
Actinobacteria (ACT), Betaproteobacteria (BET), and
Verrucomicrobiales (VER) probes in tissue sections from
two PMP patients (196 and 244) are shown. At the phylum
level we were able to detect Firmicutes, Bacteroidetes and

Actinobacteria in tissue specimens from all five patients
(Figure 4 and data not shown). Specifically within
the Proteobacterial phylum, we detected the presence of
Betaproteobacteria (Figure 4) and Gammaproteobacteria
(data not shown); at the order level, we detected the
presence of the commonly found human-associated
Verrucomicrobiales (Figure 4), as well as the Rhizobiales
(data not shown), which are commonly found within soil
environments. Additionally, using genus-specific probes we
verified the presence of Pseudomonas, Propionibacterium
and Streptococcus sp., which are known human pathogens
(data not shown). Combined, these data support our
sequence-based analysis and confirm that members of these
taxonomic groups are located within or directly associated
with the PMP tissue.
Isolation and identification of bacterial strains associated
with PMP

To help us understand the impact that these bacteria
have on disease, we isolated and characterized PMPassociated bacteria. Using microaerophilic conditions,
we were able to successfully culture 11 isolates from
eight patients. The identity of these bacterial isolates is
shown in Table 3. In vitro assays using mucin secreting
HT-29 cells indicated that at least some of these organisms are able to adhere to the mucin MUC2, which has
been shown to be one of the mucins secreted by PMP
cells. As an example, Figure 5 depicts the unclassified
Chitinophagaceae strain interacting with secreted mucin.
Importantly, one of the organisms we were able to culture from multiple patients, a Propionibacterium sp.,
was one of the more prevalent organisms identified in
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Table 2 PMP core microbiome sequences classifiable at
the genus level
Genus

Sequences

Methylobacterium

106626

Variovorax

104621

Escherichia_Shigella

88823

Propionibacterium

81731

Pseudomonas

64037

Tessaracoccus

41711

Acinetobacter

35628

Helicobacter

33441

Streptococcus

17987

Acidovorax

15911

Moraxella

8777

Sphingomonas

6731

Methylotenera

6097

Haliscomenobacter

5883

Flavobacterium

5483

Polaromonas

5046

Brevibacillus

4674

Stenotrophomonas

4565

Methylophilus

4389

Diaphorobacter

4616

Limnohabitans

4453

Curvibacter

3149

Delftia

2904

Terrimonas

2587

Ralstonia

2372

Bdellovibrio

2288

Flectobacillus

1990

Arcicella

1904

Zoogloea

1663

Microbacterium

1306

Arcobacter

848

Pedobacter

834

Lactococcus

767

Roseomonas

633

our core microbiome (Table 2) and directly detected by
ISH (Figure 4). Taken together, these data further support our sequencing results and support a potential role
for these bacteria in the maintenance or progression of
PMP disease.
Antibiotic treatment efficacy

Having identified bacteria associated with PMP, we next
tested whether antibiotic treatment could serve as an
additional treatment option for patients. To this end, we

Figure 4 Direct detection of bacterial taxa in PMP tumor tissue
by ISH. Hybridizations were carried out as described in the Materials
and Methods. Using DNA probes complementary to taxon-specific
rRNA sequences, we detected the presence of bacteria in additional
patients not included in our sequencing study (patients 196 and 244
shown). Images were selected to show positive hybridization signal
with a subset of probes used and are not intended to reflect relative
abundance within tissue specimens. FIR, Firmicutes; ACT,
Actinobacteria; BET, Betaproteobacteria; VER, Verrucomicrobiales.

designed a pilot clinical study to evaluate the efficacy of
antibiotic treatment in PMP patients. Since H. pylori
was previously identified in PMP tissue [10], the initial
treatment regimen was designed to treat this organism.
Starting in September 2007, a test group of 21 PMP
patients was treated with antibiotics in addition to
cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy using mitomycin. The antibiotic regimen
used was the Prevpac®, which includes lansoprazole,
amoxicillin, and clarithromycin, taken twice daily for
10–14 days. Seventeen of the patients received two
courses of antibiotics, one course three weeks prior to
surgery and a second course six to eight weeks following
surgery. The four additional patients only received one
course prior to surgery, since they had difficulty in tolerating the antibiotics used. The antibiotic treatment
group consisted of eight DPAM patients, 11 PMCA
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Table 3 Bacterial strains isolated from PMP tissue
samples
Isolate

Family and genus level classification

PMP191F

unclassified Chitinophagaceae (100), Niastella (70)

PMP191M

Bradyrhizobiaceae (100), Bosea (100)

PMP191C

Dermacoccaceae (100), Dermacoccus (100)

PMP196

Propionibacteriaceae (100), Propionibacterium (100)

PMP213

Propionibacteriaceae (100), Propionibacterium (100)

PMP215

Pseudonocardiaceae (100), Amycolatopsis (100)

PMP219

Propionibacteriaceae (100), Propionibacterium (100)

PMP229

Propionibacteriaceae (100), Propionibacterium (100)

PMP238

Corynebacteriaceae (100), Corynebacterium (100)

PMP267-3

Propionibacteriaceae (100), Propionibacterium (100)

PMP267B

Corynebacteriaceae (100), Corynebacterium (100)

Sequences were amplified using the 8F and 1492R primers, sequenced using
the 907R and/or 1492R primers and classified using the RDP classifier; %
bootstrap support for each classification is shown in parentheses.

patients, one patient with both diagnoses (from separate
biopsies), and one patient where the diagnosis was not
recorded. Based on a recent study, which indicated that
lymph node (LN) status is a good indicator of survival in
PMP, we divided the test patients into two major groups
based on whether they were LN positive or negative.
Thirteen of the patients in the antibiotic treatment
group were LN negative and seven patients were LN
positive. One patient did not receive a LN assessment.
Initially we compared the survival of the LN negative
PMP patients that received the antibiotic treatment to a
group of LN negative patients that had not received the
PrevPac® treatment regimen. This non-antibiotic control
group was part of a larger cohort of PMP patients that
are currently being followed. Overall, the LN negative
patients who received antibiotics showed a higher percent survival than has been previously reported (9);
when compared to the group of LN negative nonantibiotic treated patients, the difference in survival was
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statistically significant (P < 0.05, Log-rank test). However,
we noted that this comparison included antibiotic
treated patients with both DPAM and PMCA diagnosis
(six PMCA and seven DPAM), whereas patients in the
control group only had PMCA. In order to make an assessment of the antibiotic treatment efficacy that took
diagnosis into account, we next compared survival rates
of only LN negative patients with a PMCA diagnosis; we
compared the survival of the six LN negative PMCA patients in the antibiotic treatment group to a cohort of 37
LN negative PMCA patients that had not received therapy (Figure 6). As described above, patients in this control group are part of a larger group of PMP patients
currently being followed (described in (9)). The difference in survival between these two LN negative PMCA
patient groups did not reach statistical significance (P =
0.078, Log-rank test); all of the patients that received antibiotics survived, whereas only ~70% of those that did
not receive antibiotics survived. Even though this value
is not statistically significant, it does indicate a trend that
suggests that antibiotics could be beneficial. Though not
included in that comparison, it is important to note that
all seven DPAM patients who received antibiotics are
also surviving as of February, 2013. Specifically, our results suggest that antibiotics may be beneficial in
treating LN negative PMP patients, and that elimination
of bacteria before PMP has had a chance to metastasize
can extend overall survival time of LN negative PMP
patients. Importantly, the survival rate of LN positive patients within the pilot group that received antibiotic
therapy was effectively the same as those that did not
receive antibiotics (data not shown). Importantly, an
additional recent study from our group showed that
antibiotic treatment significantly reduced the number of
bacteria found in PMP tissue [28]. Thus, en masse our
results support our hypothesis that eliminating bacteria
from the affected peritoneal tissue prior to metastasis
may improve survival of patients with PMP disease.

Figure 5 Bacteria isolated from PMP tissue associates with MUC2. Isolate PMP191F (an unclassified Chitinophagaceae) was cultured with
MUC2 secreting HCT-29 cells. The rod shaped bacteria interact with cell-associated MUC2 (left) as well as secreted MUC2 (right). The positive
reaction (seen as brown color) for MUC2 staining on the bacterial cells is consistent with interaction or adherence with MUC2. The image shown
in the panel on the right is a magnification of the boxed region in the left panel.
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Figure 6 Patient survival after antibiotic treatment. Survival of
PMP LN negative PMCA patients with or without antibiotic treatment;
the red line indicates survival of patients that were treated with
antibiotics (n = 6), whereas the black line indicates patients that were
not given this treatment (n = 37). Differences in percent survival were
compared using a Log-rank statistical test, P = 0.078.

Discussion
PMP is a rare but serious disease that results in significant morbidity and mortality. As patient outcome is frequently more negative once the disease progresses to the
more severe form (PMCA), PMP is most effectively
treated prior to this transition. However, despite early
intervention, PMP patients experience frequent relapses
and the long-term prognosis for PMP patients is dismal,
with only ~30% surviving past 10 years. As such there is
still a great need for novel or supplementary treatment
options that will increase patient survival.
A previous study highlighted the fact that bacteria are
present within the peritoneum of PMP patients, but not
in the patients that did not have PMP [10]. Because the
peritoneum is typically considered to be sterile, this finding was pursued in greater detail. In the current study, we
identified a core set of bacteria that are present in PMP
tumor tissue and free mucin. The majority of the taxa
present in this group were classified as Proteobacteria, and
the overall profile of the core microbiome (Figure 3) reflects
that of the individual samples (Figure 1). Across the 11 patients in our study, the major difference in the community
structures was related to the relative abundance of bacterial
taxa. These differences can be seen at both the phylum and
lower taxonomic levels. Interestingly, the dominant phylum
present was the Proteobacteria; while this group is commonly found in and on the human body [11,13,18,19], virtually none of the healthy subject microbiomes described to
date are dominated by this phylum. On the other hand,
Proteobacteria are a dominant member of the respiratory
tract microbiome associated with cystic fibrosis (CF) patients [20,29,30]. The abundance of Proteobacteria in both
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of these disease states is perhaps the result of similarities in
the CF lung environment and PMP tissue in the peritoneum. In both CF and PMP, there is an abundance of mucin/
mucus secretion, which may enrich for the Proteobacteria
as well as some of the typically “environmental” bacteria
found in our sequence-based study (Table 2 and Additional
file 1: Table S1). While the possibility exists that these bacteria may directly utilize mucin or affect mucin secretion,
currently the exact role of these bacteria in stimulating
mucin production in this disease is unknown.
In addition to the dominance of the Proteobacterial
phylum, the PMP core microbiome also shares some additional characteristics with that of CF airways. Specifically,
there are several non-Proteobacterial genera that are
present in both microbiomes. As shown in Table 2 and
Additional file 1: Table S1, of those classifiable at the
genus level, one of the more prevalent groups detected in
our study was the Streptococcus sp. Members of this
genus, which includes the S. milleri group (SMG), have
been recently shown to be a prominent part of CF disease
[20] and are known to be associated with several types of
human disease [31-34]. Furthermore, other Streptococcus
sp. have been shown to increase virulence of other bacterial pathogens such as P. aeruginosa [35], which could
be found in PMP tissue given that members of the
Pseudomonas genus were found in the PMP core microbiome (Table 2 and Additional file 1: Table S1). A previous
study identified the carcinogenic bacterium H. pylori in
PMP tissue samples and determined that the density of H.
pylori correlated to PMP disease severity [10]. Consistent
with this study, we also detected the presence of
Helicobacter sp. in the PMP core microbiome (Table 2
and Additional file 1: Table S1). While the precise role of
these bacteria in PMP disease is unclear, H. pylori is
known to induce a pro-inflammatory response [36] and
secrete an oncogenic virulence factor [37] that may contribute to carcinogenesis and/or the maintenance of PMP
disease. While our study design did not allow us to confidently make species level taxonomic classification, the presence of Streptococcus sp., Pseudomonas sp., Helicobacter sp.
and other taxonomic groups that contain known human
pathogens in the PMP core microbiome highlights the possibility that these bacteria play a role in PMP disease and
certainly merits more detailed study.
One attractive feature of performing sequence-based bacterial community analyses is the ability to identify possible
keystone taxonomic groups or species that are enriched in a
particular body site or disease state. Recently, this feature
was exploited to identify Fusobacterium sp. as being
enriched in patients with colorectal cancer [12,17]. However, unlike those studies, for our work, there did not appear
to be any one bacterial type that was enriched in either of
the two sampling sites (tumor and mucin), or in one disease
state versus the other (DPAM vs PCMA). This finding
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perhaps suggests that it is the combination of many bacterial types present (i.e. the community structure) that is important in PMP rather than a single keystone species and
highlights the importance of studying these organisms as a
community in addition to studies focused on single bacterial types. However, we do note that as shown in Figure 1,
there are particular taxa that are more abundant in some
patients than others; as a result, we cannot completely rule
out the possibility that the increased abundance of one particular taxon/species could have an effect on disease progression. As highlighted in recent study of colorectal cancer
[38], it is possible that as our understanding of PMPassociated bacteria evolves, so will our understanding of the
role of particular taxa in the disease.
In an effort to characterize PMP-associated organisms,
we have begun to culture bacteria from PMP samples.
To date, we have successfully cultured several organisms
from multiple patients. Among those bacteria cultured
(Table 3), the Propionibacterium sp. was isolated most
frequently. Comparison of these 16S sequences to
completed genomes in GenBank indicates that these
Propionibacterium sp. are likely to be P. acnes. P. acnes
is commonly found on human skin and has been implicated in several types of human diseases including
endopthalmitis and bone infections. Interestingly, a recent ISH-based study found P. acnes in ~80% of cancerous prostates [39]. In that study, the authors were also
able to culture P. acnes from cancerous prostates and
showed that incubation with this bacterium elicited a
strong pro-inflammatory response in host cells [39],
which may be a contributing factor to disease progression. The potential role for the other cultured isolates is
less clear. However, in vitro experiments with the unclassified Chitinophagaceae isolate PMP191F indicate that this
organism does interact with the PMP-associated mucin,
MUC2 (Figure 5).
The presence of a consistent group of bacteria in all
PMP patients brings to light one distinct possibility: if
these bacteria do play a role in the maintenance of PMP
disease or PMP progression, then treatments aimed at
clearing this polymicrobial infection should improve
patient outcome. We tested this hypothesis in a pilot
clinical study using new patients as well as existing patient data. We found that treating PMP patients with a
combination of antibiotics (Prevpac®) improved overall
survival. While these pilot study findings are important
in that they strongly suggest that antibiotics may be a
viable supplementary treatment for PMP, additional
patients need to be enrolled in a larger clinical study to
confirm the positive effect of antibiotic treatment on
PMP disease. Future work will focus on optimizing
specimen transport and culture methods to increase the
recovery of bacterial isolates from PMP tissue, and on
developing an animal model of PMP, which will allow us
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to better understand the role of individual bacterial species in PMP disease. Once we have gained a more
complete understanding of the role each bacterial taxon
plays in PMP, antibiotic therapy could be tailored to target specific taxa in a particular patient.
The study presented herein characterized a previously
unknown aspect of PMP: the PMP-associated microbiome. As a result of our sequence-based analysis, direct
detection of bacterial taxa by ISH and culturing efforts,
we have identified a possible novel avenue for treating this
deadly disease. While these findings identify a conserved
microbiome and show that antibiotic treatment extends
patient survival, more work is needed to better understand
the role of bacterial communities in PMP disease and the
benefits gained from eliminating or reducing the load of
these bacteria. Finally, this study also highlights the possibility that other diseases not currently known to be linked
to the presence of bacteria may in fact be associated with
bacterial infection.
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